DUBLIN, August 8, 2013 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/f5rg4j/global) has announced the addition of the "Global Cardiovascular Drugs Market 2012-2016" report to their offering.
One of the key factors affecting market growth is the over-dependency of the market on the US. The Global Cardiovascular Drugs market has also been witnessing an increase in R&D activities. However, the increase in healthcare expenditure could be one of the factors that will contribute to the growth of this market.
The key vendors dominating this market space are AstraZeneca plc, Bristol-Myers Squibb Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi.
The other vendors mentioned in the report are Abbott Laboratories, Forest Laboratories Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Daiichi Sankyo Co. Ltd., GlaxoSmithKline plc, Solvay SA, Takeda Pharmaceutical Co. Ltd., and The Medicines Co.
Commenting on the report, an analyst from TechNavio's Healthcare team said: "In the last few years, the Healthcare industry has witnessed phenomenal growth in the APAC region. Emerging economies such as the APAC region, Eastern Europe, and Latin America hold vast growth potential. These regions are under-equipped to address the increase in the incidence of CVDs in the region. However, the increase in the incidence of CVDs and instances of patients frequently enduring long waits for therapeutic treatments are forcing healthcare organizations in the region to opt for cardiovascular drugs. Moreover, there has been substantial investment to initiate a significant number of projects in R&D across t
|SOURCE Research and Markets|
Copyright©2012 PR Newswire.
All rights reserved